Skip to main content
. 2007 Jan 18;117(2):326–336. doi: 10.1172/JCI28833

Figure 1. Effects of CQ with and without p53 activation on the regression of Myc/p53ERTAM lymphomas.

Figure 1

(A) CQ impairs tumor growth. Cells from a primary Myc/p53ERTAMtumor were harvested and passaged in vivo in 6 syngeneic C57BL/6×129F1 mice. Cells were injected subcutaneously into the flanks of mice. When tumors reached a volume of more than 1,000 mm3, mice were assigned to daily PBS i.p. or 60 mg/kg/d CQ i.p. Results shown are mean ± SD daily tumor volumes and are representative of multiple experiments. *P < 0.05. (B) CQ delays tumor recurrence after p53-induced tumor regression. Myc/p53ERTAM cells were injected subcutaneously into the flanks of 18 C57BL/6×129F1 mice. Once tumors reached a volume of more than 1,500 mm3, mice were assigned to daily treatment (arrow) with 1 mg/d TAM i.p. plus saline (TAM/PBS) or 1 mg/d TAM i.p. plus 60 mg/kg/d CQ i.p. (TAM/CQ). Results shown are daily tumor volumes (mean ± SD) for each group from a representative experiment. *P < 0.05; **P < 0.005.